Diabetologist Anoop Misra, who had been treating a 30-year-old for obesity with the weight-loss injectable drug tirzepatide (sold as Mounjaro), was surprised when the latter didn’t lose as much weight. “He had been on the medication for about two months but I didn’t see the change I expected despite a third dose escalation,” says the chairman of Fortis C-DOC Hospital for Diabetes and Allied Sciences, New Delhi. Speaking about his non-responder patient with The Indian Express, Dr Misra says, “The patient began questioning the drug after hearing that a particular pharmacy might be dispensing fake drugs. While I dismissed his fears, saying such claims could be untrue, the lack of expected weight loss was concerning. This was my first patient who had reported such an anomaly.” Then the seizure of counterfeit versions of Mounjaro KwikPen worth Rs 56 lakh in Gurugram exposed a racket that was manufacturing and selling the injections through illegal channels.…